Edwards Lifesciences Management

Management Kriterienprüfungen 3/4

Edwards Lifesciences CEO ist Bernard Zovighian , ernannt in May 2023, hat eine Amtszeit von 1.5 Jahren. Die jährliche Gesamtvergütung beträgt $12.87M , bestehend aus 7.6% Gehalt und 92.4% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.012% der Aktien des Unternehmens, im Wert von $4.84M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5.2 Jahre bzw. 4.5 Jahre.

Wichtige Informationen

Bernard Zovighian

Geschäftsführender

US$12.9m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	7.6%
Amtszeit als Geschäftsführer	1.5yrs
Eigentum des Geschäftsführers	0.01%
Durchschnittliche Amtszeit des Managements	5.2yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.5yrs

Jüngste Management Updates

Recent updates

Estimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Nov 11

Edwards Lifesciences Q3: Divesting Critical Care And Focusing On Structural Hearts

Oct 25

Bearish: Analysts Just Cut Their Edwards Lifesciences Corporation (NYSE:EW) Revenue and EPS estimates

Sep 11

Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future

Aug 30

Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E

Jul 12

Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Jun 24

Edwards Lifesciences Corp Looks Bullish (Technical Analysis)

Jun 22

Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future

May 13

Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)

May 09

When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?

Apr 29

Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Apr 15

Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear

Apr 01

Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture

Feb 21

Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)

Feb 14

Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47

Feb 08

Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly

Jan 28

The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing

Jan 14

Edwards Lifesciences: Undervalued With A Substantial Upside Potential

Jan 09

Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up

Dec 31

Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)

Dec 17

Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets

Oct 26

Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Oct 23

Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?

Oct 09

Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value

Sep 26

A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Sep 11

Edwards Lifesciences: Rising Dominance In Structural Heart Disease

Aug 21

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Bernard Zovighian im Vergleich zu den Einnahmen von Edwards Lifesciences verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	US$2b
Jun 30 2024	n/a	n/a	US$2b
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	US$13m	US$973k	US$1b
Sep 30 2023	n/a	n/a	US$1b
Jun 30 2023	n/a	n/a	US$1b
Mar 31 2023	n/a	n/a	US$1b
Dec 31 2022	US$3m	US$642k	US$2b

Vergütung im Vergleich zum Markt: BernardDie Gesamtvergütung ($USD12.87M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD12.74M).

Entschädigung vs. Einkommen: BernardDie Bezüge der Mitarbeiter sind im vergangenen Jahr um mehr als 20 % gestiegen.

Geschäftsführer

Bernard Zovighian (56 yo)

1.5yrs

Amtszeit

US$12,869,020

Vergütung

Mr. Bernard J. Zovighian serves as Chief Executive Officer and Director at Edwards Lifesciences Corp since May 11, 2023 and was its President at Edwards Lifesciences Corp since January 1, 2023 until May 11...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Bernard Zovighian	CEO & Director	1.5yrs	US$12.87m	0.012% $ 4.8m
Scott Ullem	Corporate VP & CFO	10.8yrs	US$5.95m	0.046% $ 18.5m
Donald Bobo	Corporate Vice President of Strategy & Corporate Development	8.8yrs	US$4.29m	0.035% $ 14.0m
Larry Wood	Corporate VP and Group President of TAVR & Surgical Structural Heart	1.8yrs	US$5.40m	0.030% $ 12.1m
Andrew Dahl	Principal Accounting Officer	less than a year	keine Daten	0.00030% $ 119.9k
Todd Brinton	Corporate VP of Advanced Technology & Chief Scientific Officer	5.8yrs	keine Daten	keine Daten
Mark Wilterding	Vice President of Investor Relations	no data	keine Daten	keine Daten
Arnold Pinkston	Corporate VP & General Counsel	5.2yrs	keine Daten	keine Daten
Dirksen Lehman	Corporate Vice President of Public Affairs	11.4yrs	keine Daten	keine Daten
Christine McCauley	Corporate Vice President of Human Resources	12.3yrs	keine Daten	keine Daten
Gary Sorsher	Senior Vice President of Quality & Regulatory Compliance	1.3yrs	keine Daten	keine Daten
Wayne Markowitz	GM & Senior VP of Surgical Structural Heart	1.3yrs	keine Daten	0.00021% $ 83.9k

5.2yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrenes Management: EWDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5.2 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Bernard Zovighian	CEO & Director	1.5yrs	US$12.87m	0.012% $ 4.8m
Kieran Gallahue	Independent Director	9.8yrs	US$335.06k	0.012% $ 4.9m
Paul LaViolette	Independent Director	4.3yrs	US$329.97k	0.0013% $ 523.5k
Steven Loranger	Independent Director	8.7yrs	US$335.06k	0.012% $ 4.8m
Leslie Heisz	Independent Director	8.3yrs	US$356.42k	0.0046% $ 1.8m
Nicholas Valeriani	Independent Chairman	10yrs	US$347.97k	0.012% $ 4.7m
Leslie Davis	Independent Director	less than a year	keine Daten	keine Daten
David Feinberg	Director	less than a year	keine Daten	keine Daten
Ramona Sequeira	Independent Director	4.5yrs	US$334.97k	0.0019% $ 747.3k

4.5yrs

Durchschnittliche Betriebszugehörigkeit

64yo

Durchschnittliches Alter

Erfahrener Vorstand: EWDie Vorstandsmitglieder gelten als erfahren (4.5 Jahre durchschnittliche Amtszeit).

Edwards Lifesciences Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Insider notifies of intention to sell stock

Insider exercised options and sold US$107k worth of stock

Corporate VP & CFO notifies of intention to sell stock

Insider notifies of intention to sell stock

Non-Executive Chairman of the Board exercised options and sold US$1.4m worth of stock

Corporate VP & CFO notifies of intention to sell stock

Recent updates

Estimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Insider notifies of intention to sell stock

Edwards Lifesciences Corporation Presents Data at TCT Reinforce Commitment to Structural Heart Innovation

TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation

Edwards Lifesciences Announces Results from the EARLY TAVR Trial

Edwards Lifesciences Q3: Divesting Critical Care And Focusing On Structural Hearts

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Edwards Lifesciences Corporation Provides Earnings Guidance for the Fourth Quarter and Reiterates Sales Guidance for the Full Year 2024

Edwards Lifesciences Corporation to Report Q3, 2024 Results on Oct 24, 2024

Robbins Geller Rudman & Dowd LLP Updates on Class Action Lawsuit Against Edwards Lifesciences Corporation

Insider exercised options and sold US$107k worth of stock

Edwards Launches SAPIEN 3 With Alterra Prestent in Europe for Transcatheter Pulmonic Valve Implantation

Bearish: Analysts Just Cut Their Edwards Lifesciences Corporation (NYSE:EW) Revenue and EPS estimates

Consensus revenue estimates decrease by 11%

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW).

Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future

Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?

Now 20% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 27%

Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut

Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Edwards Lifesciences Corporation Provides Earnings Guidance for the Third Quarter of 2024

Edwards Lifesciences Corporation (NYSE:EW) agreed to acquire the remaining unknown majority stake in Innovalve Bio Medical Ltd. for $300 million.

Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E

Now 15% overvalued

Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Edwards Lifesciences Corp Looks Bullish (Technical Analysis)

Now 20% overvalued

Edwards Lifesciences Announces Results from Analysis of Data from Partner Trials Examining Outcomes of Transcatheter Aortic Valve Replacement Patients with Small Annulus

Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.

Corporate VP & CFO notifies of intention to sell stock

Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future

Insider notifies of intention to sell stock

Edwards Lifesciences Corporation Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability

Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)

Non-Executive Chairman of the Board exercised options and sold US$1.4m worth of stock

When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?

Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Edwards Lifesciences Corporation to Report Q1, 2024 Results on Apr 25, 2024

Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Edwards Lifesciences Announces the Release of Data from the Hudle Study

Now 22% overvalued after recent price rise

Corporate VP & CFO notifies of intention to sell stock

Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear

Edwards Lifesciences Corporation, Annual General Meeting, May 07, 2024

Edwards Lifesciences Announces Large, Real-World Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR

Non-Executive Chairman of the Board exercised options and sold US$1.5m worth of stock

Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture

Insider notifies of intention to sell stock

Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)

Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Edwards Lifesciences Corporation Provides Earnings Guidance for the First Quarter and Full Year 2024

Non-Executive Chairman of the Board exercised options and sold US$1.5m worth of stock

Investor sentiment improves as stock rises 18%

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

Edwards Lifesciences Corporation to Report Q4, 2023 Results on Feb 06, 2024

Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly

The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing

Edwards Lifesciences: Undervalued With A Substantial Upside Potential

Corporate VP & CFO notifies of intention to sell stock

Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up

Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)

Non-Executive Chairman of the Board exercised options and sold US$1.1m worth of stock

Edwards Lifesciences Corporation Reaffirms Earnings Guidance for the Year 2023 and Provides Earnings Guidance for the Full Year 2024

Edwards Lifesciences Corporation (NYSE:EW) announces an Equity Buyback for $1,000 million worth of its shares.

Insider notifies of intention to sell stock